Overview

An Investigational Drug Study in Obese (Considerably Overweight) Patients (0364-006)

Status:
Completed
Trial end date:
2005-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety and effectiveness of an investigational drug in patients with obesity (considerably overweight).
Phase:
Phase 2
Details
Lead Sponsor:
Merck Sharp & Dohme Corp.
Treatments:
N-(3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl)-2-methyl-2-((5-(trifluoromethyl)pyridin-2-yl)oxy)propanamide